Spyglass Capital Management’s Pacira BioSciences PCRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-831,037
| Closed | -$33.9M | – | 27 |
|
|
2023
Q1 | $33.9M | Sell |
831,037
-37,649
| -4% | -$1.54M | 2.56% | 23 |
|
|
2022
Q4 | $33.5M | Sell |
868,686
-383,656
| -31% | -$14.8M | 2.69% | 21 |
|
|
2022
Q3 | $66.6M | Sell |
1,252,342
-208,292
| -14% | -$11.1M | 4.71% | 8 |
|
|
2022
Q2 | $85.2M | Sell |
1,460,634
-410,406
| -22% | -$23.9M | 4.73% | 10 |
|
|
2022
Q1 | $143M | Sell |
1,871,040
-232,125
| -11% | -$17.7M | 4.88% | 7 |
|
|
2021
Q4 | $127M | Sell |
2,103,165
-108,045
| -5% | -$6.5M | 3.36% | 18 |
|
|
2021
Q3 | $124M | Buy |
2,211,210
+93,537
| +4% | +$5.24M | 2.84% | 23 |
|
|
2021
Q2 | $129M | Buy |
2,117,673
+139,776
| +7% | +$8.48M | 2.86% | 19 |
|
|
2021
Q1 | $139M | Buy |
1,977,897
+5,327
| +0.3% | +$373K | 3.65% | 16 |
|
|
2020
Q4 | $118M | Buy |
1,972,570
+159,693
| +9% | +$9.56M | 3.62% | 16 |
|
|
2020
Q3 | $109M | Buy |
1,812,877
+282,046
| +18% | +$17M | 5.04% | 7 |
|
|
2020
Q2 | $80.3M | Buy |
1,530,831
+340,294
| +29% | +$17.9M | 4.97% | 6 |
|
|
2020
Q1 | $39.9M | Buy |
1,190,537
+333,710
| +39% | +$11.2M | 4.51% | 10 |
|
|
2019
Q4 | $38.8M | Buy |
856,827
+399,577
| +87% | +$18.1M | 4.98% | 5 |
|
|
2019
Q3 | $17.4M | Buy |
457,250
+77,641
| +20% | +$2.96M | 4.62% | 9 |
|
|
2019
Q2 | $16.5M | Buy |
379,609
+141,282
| +59% | +$6.14M | 5.22% | 5 |
|
|
2019
Q1 | $9.07M | Buy |
238,327
+118,170
| +98% | +$4.5M | 3.51% | 17 |
|
|
2018
Q4 | $5.17M | Buy |
+120,157
| New | +$5.17M | 3.87% | 17 |
|